Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 222-148-7 | CAS number: 3371-33-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in chemico
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- 19 December 2016 - 15 May 2017
- Reliability:
- 1 (reliable without restriction)
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 017
- Report date:
- 2017
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 442C (In Chemico Skin Sensitisation: Direct Peptide Reactivity Assay (DPRA))
- Version / remarks:
- 2015
- Qualifier:
- according to guideline
- Guideline:
- other: Direct Peptide Reactivity Assay (DPRA) for Skin Sensitization Testing, DB-ALM Protocol no 154,
- Version / remarks:
- 2013
- GLP compliance:
- yes (incl. QA statement)
- Type of study:
- other: Direct Peptide Reactivity Assay
- Justification for non-LLNA method:
- This test method is able to detect chemicals that cause skin sensitisation and allows for hazard identification in accordance with UN GHS “Category 1”. Data generated with this method may be not sufficient to conclude on the absence of skin sensitisation potential of chemicals and should be considered in the context of an integrated approach such as IATA, combining them with other complementary information e.g., derived from in vitro assays addressing other key events of the adverse outcome pathway.
Test material
- Reference substance name:
- 1-(3,5-dihydroxyphenyl)-2-[[2-(4-hydroxyphenyl)-1-methylethyl]amino]ethan-1-one hydrobromide
- EC Number:
- 222-148-7
- EC Name:
- 1-(3,5-dihydroxyphenyl)-2-[[2-(4-hydroxyphenyl)-1-methylethyl]amino]ethan-1-one hydrobromide
- Cas Number:
- 3371-33-3
- Molecular formula:
- C17H19NO4.BrH
- IUPAC Name:
- 1-(3,5-dihydroxyphenyl)-2-{[1-(4-hydroxyphenyl)propan-2-yl]amino}ethan-1-one hydrobromide
- Test material form:
- solid: particulate/powder
Constituent 1
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material:TH 1165 Ketone II BR (Batch No: 159)
- Expiration date of the lot/batch: 30 April 2017
- Purity test date:No details reported.
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: at room temperature
- Stability under test conditions:stable at storgae conditions
- Solubility and stability of the test substance in the solvent/vehicle: The test item was prepared immediatlely prior to use.
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: No details reported.
- Preliminary purification step (if any):No details reported.
- Final dilution of a dissolved solid, stock liquid or gel:No details reported.
- Final preparation of a solid:No details reported.
In chemico test system
- Details on the study design:
- - Preparation of the Test Item
The test item was freshly prepared immediately prior to use, unless stability data demonstrate the acceptability of storage. The test item was pre-weighed into a glass vial and was dissolved in an appropriate solvent previously determined in a pre-experiment. A stock solution with a concentration of 100 mM was prepared.
- Controls
Reference controls, co-elution controls and a positive control (PC) were set up in parallel to the test item in order to confirm the validity of the test.
- Positive Control
Cinnamic aldehyde ((2E)-3-phenylprop-2-enal) was solved in acetonitrile and was used as positive control. A stock concentration of 100 mM was prepared and was included in every assay run for both peptides.
- Co-elution Control
Co-elution controls were set up in parallel to sample preparation but without the respective peptide solution. The controls were used to verify whether a test chemical absorbs at 220 nm and co-elutes with the cysteine or lysine peptide. The co-elution controls were prepared for every test item preparation and the positive control and were included in every assay run for both peptides.
- Reference Control
Reference controls were set up in parallel to sample preparation in order to verify the validity of the test run.
Reference control A was prepared using acetonitrile in order to verify the accuracy of the calibration curve for peptide quantification. Its replicates were injected in the beginning of each HPLC run.
Reference control B was prepared using acetonitrile in order to verify the stability of the respective peptide over the analysis time. Its replicates were injected in the beginning and in the end of each HPLC run.
Reference control C was set up for the test item and the positive control. Reference control C for the test item was prepared using the respective solvent used to solubilize the test item. RC C for the positive control was prepared using acetonitrile. Reference control C was used to verify that the solvent does not impact the percent peptide depletion (PPD). Additionally reference control C was used to calculate PPD. Reference control C was included in every assay run for both peptides and was injected together with the samples.
- Test System
For HPLC system and HPLC mobile phase see table 1 and 2.
- Peptides
15.20 mg cysteine peptide with an amino acid sequence of Ac-RFAACAA were pre-weighed in a vial and dissolved in a defined volume (29.52 mL) of a phosphate buffer with pH 7.5 to reach a concentration of 0.667 mM.
19.44 mg lysine peptide with an amino acid sequence of Ac RFAAKAA were pre-weighed in a vial and dissolved in a defined volume of ammonium acetate buffer with pH 10.2 (36.32 mL) to reach a concentration of 0.667 mM.
All peptides used for this study were stored at -80 °C and protected from light. Peptides were thawed only immediately prior to use.
- Dose Groups
Reference Control C (solvent control): undiluted
Test Item: 100 mM stock solution
Positive control: 100 mM stock solution
- Pre-Experiments
Solubility of the test item was determined prior to the main experiment and was tested at the highest final concentration applied in the study (100 mM) The test item was dissolved in the following solvents suitable for the test:
acetonitrile
dist. water
isopropanol
acetone
DMSO : acetonitrile 1:10 (v/v)
DMSO : acetonitrile 1:10 (v/v)
Methanol
Since the test item gave a stable solution in Methanol, Methanol was chosen as suitable vehicle.
- Experimental Procedure
Incubation of the Test Item with the Cysteine and Lysine Peptide
The test item solutions were incubated with the cysteine and lysine peptide solutions in glass vials using defined ratios of peptide to test item (1:10 cysteine peptide, 1:50 lysine peptide). The reaction solutions were left in the dark at 25 ± 2.5 °C for 24 ± 2 h before running the HPLC analysis. Reference controls, co-elution controls as well as the positive control were set up in parallel. Samples were prepared according to the scheme described in table 3.
Test item solutions were inspected on a visual basis for the formation of precipitates, turbidity and phase separation prior and after HPLC analysis. If a precipitate or phase separation was observed after the reaction period and prior to the HPLC analysis, samples might have been centrifuged at low speed (100 400x g) to force precipitates to the bottom of the vial.
After the incubation period of 24 ± 2 h the test item was analysed in triplicate for both peptides using HPLC.
- Data Analysis:
The concentration of the cysteine and lysine peptide was determined in each sample form absorbance at lambda = 220 nm, measuring the area of the appropriated peaks (peak area (PA)) and calculating the concentration of peptide using the linear calibration curves derived from the standard solutions. The percent peptide depletion (PPD) was calculated according to the following formula:
PPD=(1-((Peptide Peak Area in the Replicate Injection)/(Mean Peptide Peak Area in Reference Control C)))*100
Sensitising potential of the test item is predicted from the mean cysteine and lysine PPD value. The test item is considered positive to be a skin sensitiser in accordance with UN GHS “Category 1”, if the mean depletion of both peptides exceeds the threshold of the respective prediction model. Negative depletion is considered as “0” when calculating the mean. Sensitizing potential might not be predictable if the test item was incubated using a concentration differently from 100 mM.
By using the prediction model 1 (cysteine 1:10 / lysine 1:50 prediction model) shown in table 4 the threshold of 6.38% average peptide depletion was used to support the discrimination between skin sensitisers and non-sensitisers. Application of the prediction model for assigning a test item to a reactivity class (i.e. low, moderate or high reactivity) may perhaps prove useful to inform potency assessment within the framework of an IATA. In the framework of an IATA the test substance may be considered as non-sensitiser to skin in accordance with UN GHS “No Category” if the mean depletion of both peptides is below 6.38% (see Table 4 and 5).
- Acceptance Criteria
The run meets the acceptance criteria if:
the standard calibration curve has a r² > 0.99,
the mean percent peptide depletion (PPD) value of the three replicates for the positive control is between 60.8% and 100% for the cysteine peptide and the maximum standard deviation (SD) for the positive control replicates is < 14.9%,
the mean percent peptide depletion (PPD) value of the three replicates for the positive control is between 40.2% and 69.0% for the lysine peptide and the maximum SD for the positive control replicates is < 11.6%,
the mean peptide concentration of the three reference controls A replicates is 0.50 ± 0.05 mM,
the coefficient of variation (CV) of peptide peak areas for the six reference control B replicates and three reference control C replicates in acetonitrile is < 15.0%.
The results of the test item meet the acceptance criteria if:
the maximum standard deviation (SD) for the test chemical replicates is < 14.9% for the cysteine percent depletion (PPD),
the maximum standard deviation (SD) for the test chemical replicates is < 11.6% for the lysine percent depletion (PPD),
the mean peptide concentration of the three reference controls C replicates in the appropriate solvent is 0.50 ± 0.05 mM.
Results and discussion
- Positive control results:
- The reactivity of the positive control towards the cysteine peptide and peptide were identified correctly and both runs were valid.
In vitro / in chemico
Results
- Key result
- Run / experiment:
- other: Cysteine Peptide Depletion
- Parameter:
- other: % mean peptide depletion
- Value:
- 100
- Vehicle controls validity:
- not applicable
- Negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Remarks on result:
- positive indication of skin sensitisation
- Other effects / acceptance of results:
- Pre-Experiments:
Since the test item gave a stable solution in Methanol, Methanol was chosen as suitable vehicle.
Precipitation and Phase Separation:
All test item solutions were freshly prepared immediately prior to use.
For the 100 mM stock solution of the test item no turbidity or precipitation was observed when diluted with the cysteine peptide solution.
For the 100 mM stock solution of the test item no turbidity or precipitation was observed when diluted with the lysine peptide solution.
After the 24 h ± 2 h incubation period but prior to the HPLC analysis samples of the cysteine peptide run were inspected for precipitation, turbidity or phase separation. Precipitation was observed for the samples of the positive control and the test item. Samples were not centrifuged prior to the HPLC analysis.
After the 24 h ± 2 h incubation period but prior to the HPLC analysis samples of the lysine peptide run were inspected for precipitation, turbidity or phase separation. Turbidity and phase separation was observed for the samples of the positive control. Samples were not centrifuged prior to the HPLC analysis.
Co-elution with the Peptide Peaks:
Co-elution of the test item with the lysine peptide peak was observed. Therefore, data were interpreted using Prediction Model 2.
Results Calibration Curve
Cysteine Peptide Calibration Curve: y = 8439.71x-31.13; R² = 0.9997
Lysine Peptide Calibration Curve: y = 8464.89x+4.68; R² = 0.9999
For detailed results see table 6 to10.
Any other information on results incl. tables
Table 6: Results of the Cysteine Peptide Depletion
Cysteine Peptide |
||||||
Sample |
Peak Area |
Peptide Conc. [mM] |
Peptide Depletion [%] |
Mean Peptide Depletion [%] |
SD of Peptide Depletion [%] |
CV of Peptide Depletion [%] |
Positive Control |
906.9033 |
0.1111 |
78.63 |
78.90 |
0.58 |
0.74 |
867.1926 |
0.1064 |
79.57 |
||||
912.4229 |
0.1118 |
78.50 |
||||
Test Item |
0.0000 |
0.0037 |
100.00 |
100.00 |
0.00 |
0.00 |
0.0000 |
0.0037 |
100.00 |
||||
0.0000 |
0.0037 |
100.00 |
Since the co-elution control (only containing test item and solvent) showed a peak at the retention time of the cysteine peptide with a peak area of 284.9609, the peak areas detected for the peptide in the test item samples might not (only) represent the remaining cysteine peptide. Therefore, the true peptide depletion might be higher and underestimation of the sensitizing potential is possible.
Table 7: Results of the Lysine Peptide Depletion
Lysine Peptide |
||||||
Sample |
Peak Area |
Peptide Conc. [mM] |
Peptide Depletion [%] |
Mean Peptide Depletion [%] |
SD of Peptide Depletion [%] |
CV of Peptide Depletion [%] |
Positive Control |
2051.3940 |
0.2418 |
52.31 |
51.62 |
0.72 |
1.39 |
2078.4993 |
0.2450 |
51.68 |
||||
2113.1423 |
0.2491 |
50.87 |
||||
Test Item |
2107.8921* |
n.a. |
n.a. |
n.a. |
n.a. |
n.a. |
2159.4229* |
n.a. |
n.a. |
||||
2098.2346* |
n.a. |
n.a. |
* Since co-elution of the test substance with the lysine peptide was observed, the given peak areas of the lysine peptide in combination with the test item are considered as insignificant. Therefore, they were not used for calculation or evaluation.
Table 8: Categorization of the Test Item
Predicition Model |
Prediction Model 1 |
Prediction Model 2 |
||||
Test Substance |
Mean Peptide Depletion [%] |
Reactivity Category |
Prediction |
Mean Peptide Depletion [%] |
Reactivity Category |
Prediction |
Test Item |
n.a.* |
n.a.* |
n.a.* |
100.00 |
High Reactivity |
sensitizer |
Positive Control |
65.26 |
High Reactivity |
sensitizer |
78.90 |
Moderate Reactivity |
sensitizer |
* Not applicable due to co-elution of the test substance with the lysine peptide
Table 9: Acceptance Criteria for Cysteine Peptide
Cysteine Peptide Run |
|||
Acceptance Criterion |
Range |
Value |
pass/fail |
coefficient of determination |
R² > 0.99 |
0.9997 |
pass |
mean peptide concentration of RC A |
0.45 = x = 0.55 mM |
0.5056 |
pass |
mean peptide concentration of RC C (PC) |
0.45 = x = 0.55 mM |
0.5066 |
pass |
mean peptide concentration of RC C (TI) |
0.45 = x = 0.55 mM |
0.5003 |
pass |
CV of the peak area of RC B |
< 15% |
1.29 |
pass |
CV of the peak area of RC C (PC) |
< 15% |
0.59 |
pass |
CV of the peak area of RC C (TI) |
< 15% |
0.59 |
pass |
mean peptide depletion of the PC |
60.8% < x < 100% |
78.90 |
pass |
SD of peptide depletion of the PC replicates |
< 14.9% |
0.58 |
pass |
SD of peptide depletion of the TI replicates |
< 14.9% |
1.05 |
pass |
Table 10: Acceptance Criteria for Lysine Peptide
Lysine Peptide Run |
|||
Acceptance Criterion |
Range |
Value |
pass/fail |
coefficient of determination |
R² > 0.99 |
0.9999 |
pass |
mean peptide concentration of RC A |
0.45 = x = 0.55 mM |
0.5075 |
pass |
mean peptide concentration of RC C (PC) |
0.45 = x = 0.55 mM |
0.5076 |
pass |
mean peptide concentration of RC C (TI) |
0.45 = x = 0.55 mM |
0.5073 |
pass |
CV of the peak area of RC B |
< 15% |
0.23 |
pass |
CV of the peak area of RC C (PC) |
< 15% |
0.18 |
pass |
CV of the peak area of RC C (TI) |
< 15% |
0.52 |
pass |
mean peptide depletion of the PC |
40.2% < x < 69.0% |
51.62 |
pass |
SD of peptide depletion of the PC replicates |
< 11.6% |
0.72 |
pass |
SD of peptide depletion of the TI replicates |
< 11.6% |
n.a.* |
pass |
* Not applicable due to co-elution of the test substance with the lysine peptide.
Applicant's summary and conclusion
- Interpretation of results:
- Category 1 (skin sensitising) based on GHS criteria
- Conclusions:
- In this study under the given conditions the test item showed moderate reactivity towards the cysteine peptide. Based on the results of this study, the test item can be classified as a “sensitiser” in accordance with UN GHS “Category 1”.
- Executive summary:
The in chemico direct peptide reactivity assay (DPRA) enables detection of the sensitising potential of a test item by quantifying the reactivity of test chemicals towards synthetic peptides containing either lysine or cysteine.
In the present study the test item was dissolved in Methanol. Based on a molecular weight of 382.26 g/mol a 100 mM stock solution was prepared. The test item solutions were tested by incubating the samples with the peptides containing either cysteine or lysine for 24 ± 2 h at 25 ± 2.5 °C. Subsequently samples were analysed by HPLC.
After the 24 h ± 2 h incubation period but prior to the HPLC analysis samples of the cysteine peptide run were inspected for precipitation, turbidity or phase separation. Precipitation was observed for the samples of the positive control. No centrifugation was necessary to perform the HPLC analysis.
After the HPLC run samples of the lysine peptide run were inspected for precipitation, turbidity or phase separation. Turbidity and phase separation was observed for the samples of the positive control. No centrifugation was necessary to perform the HPLC analysis.
Since the reactivity of the positive control towards the cysteine peptide and peptide were identified correctly and both runs were valid the precipitation and phase separation was considered as irrelevant.
Co-elution of test itemwith both peptide peaks wasobserved, therefore prediction model 2 is used for data interpretation. However, evaluation of the cysteine peptide was possible, since the peak at the retention time of the peptide but resulting from the test item would not have overlaid the peptide peak regarding peak area and height. Therefore, sensitisingpotential of the test item was predicted from the mean peptide depletion of the cysteine peptide by comparing the peptide concentration of the test item treated samples to the corresponding reference control C.
The 100 mM stock solution of the test item showed high reactivity towards the cysteine peptide, the mean depletion was > 13.89% (100%). Based on the prediction model 2 the test item is considered as a "sensitiser".
The 100 mM stock solution of the positive control (cinnamic aldehyde) showed high reactivity towards the synthetic peptides. The mean depletion of both peptides was 65.26% (Positive Sensitiser DPRA Prediction, Moderate Reactivity; Prediction Model 2).
The data generated with this test should be considered in the context of integrated approached such as IATA, combining the result with other complementary information, e.g. derived from in vitro assays addressing other key events of the skin sensitisation AOP.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.